Related references
Note: Only part of the references are listed.Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2021)
Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus
Kerry A. Casey et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
Khaled Mahmoud et al.
RHEUMATOLOGY (2021)
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Raj Tummala et al.
LUPUS SCIENCE & MEDICINE (2021)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
Yasser M. El-Sherbiny et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity
Antonios Psarras et al.
NATURE COMMUNICATIONS (2020)
Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus
Alessandra Tesser et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus
Ahmed S. Zayat et al.
RHEUMATOLOGY (2019)
Novel paradigms in systemic lupus erythematosus
Thomas Doerner et al.
LANCET (2019)
Whole exome sequencing in childhood-onset lupus frequently detects single gene etiologies
Irit Tirosh et al.
PEDIATRIC RHEUMATOLOGY (2019)
Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus
Khaled Mahmoud et al.
RHEUMATOLOGY (2019)
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
Vilija Oke et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa
Mrinal K. Sarkar et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
Jayne Little et al.
RHEUMATOLOGY (2018)
A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features
Y. M. El-Sherbiny et al.
SCIENTIFIC REPORTS (2018)
Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds
Taro Iwamoto et al.
LUPUS SCIENCE & MEDICINE (2018)
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
Jeffrey M. Riggs et al.
LUPUS SCIENCE & MEDICINE (2018)
Detection of interferon alpha protein reveals differential levels and cellular sources in disease
Mathieu P. Rodero et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop
Jasmine N. Stannard et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Points to consider for skin ulcers in systemic sclerosis
Felice Galluccio et al.
RHEUMATOLOGY (2017)
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody
Li Peng et al.
MABS (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Qualitative validation of the FACIT-Fatigue scale in systemic lupus erythematosus
M. Kosinski et al.
LUPUS (2013)
Activation of the interferon patnway is dependent upon autoantibodies in African-American SLE patients, but not in European-American SLE patients
Kichul Ko et al.
FRONTIERS IN IMMUNOLOGY (2013)
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
Brandon W. Higgs et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Network Analysis of Associations Between Serum Interferon-α Activity, Autoantibodies, and Clinical Features in Systemic Lupus Erythematosus
Corinna E. Weckerle et al.
ARTHRITIS AND RHEUMATISM (2011)
Pediatric Lupus-Are There Differences in Presentation, Genetics, Response to Therapy, and Damage Accrual Compared with Adult Lupus?
Rina Mina et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2010)
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
David Isenberg et al.
RHEUMATOLOGY (2010)
Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus
Guillermo J. Pons-Estel et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN alpha antibody, in systemic lupus erythematosus
Yihong Yao et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus
Xuebing Feng et al.
ARTHRITIS AND RHEUMATISM (2006)
Expression of interferon β in synovial tissue from patients with rheumatoid arthritis:: comparison with patients with osteoarthritis and reactive arthritis
J van Holten et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus
J Albrecht et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
KA Kirou et al.
ARTHRITIS AND RHEUMATISM (2005)
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
EC Baechler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies
AA Bengtsson et al.
LUPUS (2000)
Share Paper
